Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;8(2):74-82.
doi: 10.1177/24755303231155118. Epub 2023 Mar 21.

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

Wayne P Gulliver  1 , Kyoungah See  2 , Baojin Zhu  2 , Bruce W Konicek  2 , Ryan W Harrison  3 , Robert R McLean  3 , Samantha J Kerti  3 , Russel T Burge  2   4 , Craig L Leonardi  5
Affiliations

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

Wayne P Gulliver et al. J Psoriasis Psoriatic Arthritis. 2023 Apr.

Abstract

Background: Dermatologists would benefit from an easy to use psoriasis severity assessment tool in the clinic.

Objective: To develop psoriasis assessment tools to predict PASI and Dermatology Life Quality Index (DLQI) using simple measures typically collected in clinical practice.

Methods: Data included 33 605 dermatology visits among plaque psoriasis patients enrolled in the CorEvitas Psoriasis Registry (4/15/15-7/11/20). Performance (adjusted coefficient of determination [R2 adj], root mean square error [RMSE]) in predicting PASI and DLQI was assessed for 16 different linear regression models (specified a priori based on combinations of BSA, Investigator's Global Assessment [IGA], itch, skin pain, patient global assessment, age, sex, BMI, comorbidity index, prior biologic use), and 2 stepwise selection models and 1 elastic net model based on 56 available variables. For each prediction model, concordance (sensitivity, specificity) of predicted PASI75, PASI90 and DLQI 0/1 with observed values was evaluated.

Results: Mean (SD) age, BSA, and PASI were 51 (14) years, 6 (11), and 4 (6), respectively; 46% were women, and 87% were biologic experienced. A model predicting PASI using BSA plus IGA performed best among a priori specified models (R2 adj = .72, RMSE = 2.93) and only marginally worse than models including additional variables (R2 adj range .64-.74, RMSE range 2.82-3.36). Models including IGA had the best concordance between predicted and observed PASI75 (sensitivity range 83-85%, specificity range 88-91%) and PASI90 (sensitivity range 76-82%, specificity range 94-98%). DLQI prediction was limited.

Conclusion: An assessment tool for psoriasis including BSA and IGA may be an ideal option to predict PASI in a clinic setting.

Keywords: DLQI; PASI; patient-reported outcome measures; psoriasis; psoriasis assessment tool.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: WG-Grants/research support: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. Honoraria for Ad Boards/Invited Talks/Consultation: AbbVie, Actelion, Amgen, Arylide, Bausch Health, Boehringer, Celgene, Cipher, Eli Lilly, Galderma, Janssen, LEO Pharma, Merck, Novartis, PeerVoice, Pfizer, Sanofi-Genzyme, Tribute, UCB, Valeant. Other: Clinical trials (study fees): AbbVie, Asana Biosciences, Astellas, Boerhinger-Ingleheim, Celgene, CorEvitas/National Psoriasis Foundation, Devonian, Eli Lilly, Galapagos, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, UCB; KS, BZ, BK, RB-Employee/Stock, Eli Lilly and Company; RWH, RRM, SJK (former), Employee of CorEvitas, LLC (formerly Corrona, LLC); CL-Consultant/Advisory Board for Abbvie, Amgen, Boehringer-Ingelheim, Dermira, Eli Lilly, Janssen, Leo, Pfizer, Sandoz, UCB and Vitae, Investigator for Actavis, Abbvie, Allergan, Amgen, Boehringer-Ingelheim, Celgene, Coherus, Cellceutix, CorEvitas, Dermira, Eli Lilly, Galderma, Glenmark, Janssen, Leo Pharma, Merck, Novartis, Novella, Pfizer, Sandoz, Sienna, Stiefel, UCB and Wyeth, Speaker bureau for Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Ortho Dermatologics, Sun Pharmaceuticals, and UCB.

Figures

Figure 1.
Figure 1.
Heatmap of Pearson correlations of BSA, PASI, itch, skin pain, PGA, and DLQI among the 16 840 patient-visits in the psoriasis assessment model development training dataset.
See this image and copyright information in PMC

References

    1. Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: Results from ESTEEM 1 and ESTEEM 2. J Drugs Dermatol. 2017;16(2):147-153. - PubMed
    1. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: Quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943. DOI: 10.1038/jid.2009.391 - DOI - PubMed
    1. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:10-16. DOI: 10.1111/j.1468-3083.2009.03562.x - DOI - PubMed
    1. Psoriasis: Assessment and Management of Psoriasis. London. 2012.
    1. Manalo IF, Gilbert KE, Wu JJ. An updated survey for the 2007-2013 period of randomized controlled trials for psoriasis: Treatment modalities, study designs, comparators, outcome measures and sponsorship. J Eur Acad Dermatol Venereol. 2015;29(10):1945-1950. DOI: 10.1111/jdv.13089 - DOI - PubMed

LinkOut - more resources